Latest News

eye on pharma graphic
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab

December 6th 2023

Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.

Clinical trial | Image credit: photon_photo -
BioRationality: Efficacy Testing and Interchangeability of Biosimilar Remains a Dogma for Most

December 4th 2023

Image credit: Aliaksandr Marko |
Confusion Persists Around the Interchangeability Designation for Biosimilars

November 23rd 2023

eye on pharma banner
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar

November 22nd 2023

injectable pens
BioRationality: FDA Publishes Results of First Meta-Analysis to Conclude All Biosimilars Are Interchangeable

November 20th 2023

Video Interviews
CfB Podcast Banner
"SEEING EYE TO EYE:  Exploring Different Perspectives on Ophthalmology Biosimilars SEEING EYE TO EYE:  Exploring Different Perspectives on Ophthalmology Biosimilars" with the CfB logo and an image of an eye
CfB podcast banner
CfB podcast banner
podcast banner
image of adalimumab biosmilar eveloped by alvotech prefilled syring
canadian flag on a mountain
CfB podcast banner
CfB podcast banner
Cfb podcast banner

More News

© 2023 MJH Life Sciences

All rights reserved.